Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib

The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor acalabrutinib was developed...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Bye, Alexander P., Unsworth, Amanda J., Desborough, Michael J., Hildyard, Catherine A. T., Appleby, Niamh, Bruce, David, Kriek, Neline, Nock, Sophie H., Sage, Tanya, Hughes, Craig E., Gibbins, Jonathan M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2017
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728643/
https://ncbi.nlm.nih.gov/pubmed/29296914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011999
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы